GlassScriptPhysician profile
Lisa Jackson Simmons
NPI 1790773737
$11,108.04
in general payments reported to CMS, 2019-2025
78 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,594 · 2020: $2,849 · 2021: $1,067 · 2022: $1,442 · 2023: $184 · 2024: $127 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136 · Education: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.56 |
| Education | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,002.58 | 2019-2025 | Tagrisso, Lynparza, Enhertu |
| Regeneron Healthcare Solutions, INC. | $965.08 | 2020-2025 | Lynozyfic, Libtayo |
| Novartis Pharmaceuticals Corporation | $889.22 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $603.38 | 2019-2025 | Rybrevant, Talvey, Tecvayli |
| Pfizer INC. | $569.10 | 2019-2025 | |
| Genentech USA, INC. | $430.70 | 2019-2025 | Polivy |
| Octapharma USA, INC. | $359.55 | 2019 | |
| Merck Sharp & Dohme LLC | $304.50 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $302.84 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $285.00 | 2019-2025 | |
| Amgen INC. | $263.42 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $259.33 | 2019-2022 | |
| Astellas Pharma US INC | $239.21 | 2019-2025 | Vyloy |
| Abbvie INC. | $196.03 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.23 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.